Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMARIN CORPORATION PLC (ADR)

(EH3A)
Real-time Estimate Quote. Real-time Estimate Tradegate - 01/27 03:13:54 am
3.065 EUR   +1.64%
01/26European ADRs Move Higher in Wednesday Trading
MT
01/25European ADRs Move Lower in Tuesday Trading
MT
01/11European ADRs Nudge Lower in Tuesday Trading
MT
SummaryNewsRatingsCalendarCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Amarin Corporation plc (ADR) : Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy

05/22/2013 | 06:54am EST

BEDMINSTER, N.J., and DUBLIN, Ireland, May 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa® (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy.

The claims in this allowed application cover a method to reduce triglycerides in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also receiving statin therapy (whether in fixed or non-fixed dose formulation)  using an amount of Vascepa effective to reduce triglycerides without substantially increasing low density lipoprotein cholesterol (LDL-C).    

"Through our findings from conversations with thought leaders and other clinicians during the launch of Vascepa, we've confirmed that many patients on therapies intended for lowering triglycerides are also on statins.  The claims in this allowed application cover the administration of a pharmaceutical composition comprised of EPA in conjunction with a stain, using either a fixed or non-fixed dose, to lower triglycerides without increasing LDL-C, otherwise known as bad-cholesterol," stated Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin.

A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, after issuance of the patent.

This application is part of an expanding patent portfolio for Amarin with 23 patent applications now either issued or allowed with the USPTO and over 30 additional applications pending in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States, including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA and available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about whether the subject patent would be issued and adequately protect Vascepa against competition, the expiration date of the pending patent, Amarin's plan to list the patent, when issued, in FDA's Orange Book, Amarin's plan to protect the commercial potential of Vascepa, the future status of pending patent applications, planned regulatory submissions and expected action dates. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: events that could interfere with the issuance of a patent, or once issued, the continued validity or enforceability of a patent; Amarin's ability generally to maintain adequate patent protection and successfully enforce patent claims against third parties; commercializing Vascepa without violating the intellectual property rights of others; and uncertainties associated generally with research and development, clinical trial enrollment in Amarin's REDUCE-IT trial and related regulatory submissions, action dates and approvals. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Joseph Bruno

         Investor Relations and Corporate Communications

         Amarin Corporation

         In U.S.: +1 (908) 719-1315

         investor.relations@amarincorp.com
Source: Amarin Corporation plc

News Provided by Acquire Media

distributed by

© Publicnow 2013
All news about AMARIN CORPORATION PLC (ADR)
01/26European ADRs Move Higher in Wednesday Trading
MT
01/25European ADRs Move Lower in Tuesday Trading
MT
01/11European ADRs Nudge Lower in Tuesday Trading
MT
01/10European ADRs Move Lower in Monday Trading
MT
01/10AMARIN : January 2022 Investor Deck
PU
01/10AMARIN : Provides Preliminary 2021 Revenue and Outlook for 2022 - Form 8-K
PU
01/10AMARIN CORP PLCUK : Results of Operations and Financial Condition, Change in Directors or ..
AQ
01/10Amarin Corporation plc Appoints Per Wold-Olsen as A Director
CI
01/10Amarin Provides Q4, Full-Year Outlook
MT
01/10Amarin Provides Preliminary 2021 Revenue and Outlook for 2022
AQ
More news
Analyst Recommendations on AMARIN CORPORATION PLC (ADR)
More recommendations
Managers and Directors
Karim Mikhail President, Chief Executive Officer & Director
Michael W. Kalb Chief Financial Officer & Senior Vice President
Lars G. Ekman Non-Executive Chairman
Steven B. Ketchum Chief Scientific Officer & Executive VP
Rebecca Juliano Senior VP-Clinical Research & Development
Sector and Competitors
1st jan.Capi. (M$)
AMARIN CORPORATION PLC (ADR)1 357
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.11%47 873
BIONTECH SE-37.66%38 812